Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TBC1 domain family member 23 (TBC1D23) is a highly conserved, ubiquitously expressed protein that functions as an adapter essential for membrane trafficking, specifically mediating endosome-to-Golgi transport of certain cargo proteins by bridging endosomal vesicles with the Golgi apparatus[3][1][5]. Structurally, TBC1D23 features a catalytically inactive N-terminal TBC domain (not an active Rab GTPase-activating protein), a rhodanese-like domain (catalytically inactive in the sulfurtransferase/phosphatase sense), and a C-terminal pleckstrin homology (PH) domain[1][3][5]. The TBC and rhodanese domains interact with Golgi-localized proteins golgin-97 and golgin-245, while the PH domain binds components of the WASH complex on endosomes[3][5][7]. TBC1D23 is critical for neuronal development, and its mutations underlie pontocerebellar hypoplasia (PCH), a group of severe neurodevelopmental disorders[3][5]. Its main function is as a scaffold/adaptor in vesicular transport pathways, not as an enzyme or classical receptor, and it does not possess Rab-GAP or rhodanese catalytic activity[1][3][5]. There are currently no drugs known to target TBC1D23[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TBC1 domain family member 23 (TBC1D23).